Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

[A health system ill at ease with itself].

Degos L.

Presse Med. 2017 Apr;46(4):355-357. doi: 10.1016/j.lpm.2017.03.012. Epub 2017 Apr 14. French. No abstract available.

PMID:
28413144
2.

Scientific Panel for Health: better research for better health.

Sipido K, Degos L, Frackowiak R, Ganten D, Hofstraat H, Horvath I, Luyten F, Manns M, Oertel W, Zima T.

Lancet. 2016 Aug 27;388(10047):865-6. doi: 10.1016/S0140-6736(16)31426-X. Epub 2016 Aug 25. No abstract available.

PMID:
27597458
3.

[History of acute promyelocytic leukemia].

Degos L.

Rev Prat. 2015 Oct;65(8):1114-8. French. No abstract available.

PMID:
26749720
4.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

5.

[Confronted to medical error, emphasize its positive aspects].

Degos L.

Rev Med Interne. 2015 May;36(5):303-6. doi: 10.1016/j.revmed.2014.10.359. Epub 2014 Nov 22. French. No abstract available.

PMID:
25467299
6.

N'OUBLIONS PAS DEMAIN.

Degos L, Aurengo A.

Bull Acad Natl Med. 2014 Dec;198(9):1629-32. French. No abstract available.

PMID:
27356364
7.

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Rahmé R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Adès L.

Leukemia. 2014 Dec;28(12):2422-4. doi: 10.1038/leu.2014.240. Epub 2014 Aug 21. No abstract available.

PMID:
25142818
8.

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.

Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, Labarthe Ad, Maarek O, Cassinat B, Adès L, Baruchel A, Degos L, Azoulay E, Dombret H.

Eur J Cancer. 2014 Apr;50(6):1159-68. doi: 10.1016/j.ejca.2013.11.023. Epub 2014 Jan 15.

PMID:
24440088
9.

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.

Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P; European APL group.

Am J Hematol. 2013 Jul;88(7):556-9. doi: 10.1002/ajh.23451. Epub 2013 Jun 12.

10.

Two faces of patient safety and care quality: a Franco-American comparison.

Degos L, Rodwin VG.

Health Econ Policy Law. 2011 Jul;6(3):287-94.

PMID:
21823247
11.

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.

Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux P, Degos L, Chomienne C, Chevret S, Dombret H.

Oncotarget. 2010 May;1(1):34-42.

12.

[Managing conflicts of interest for more confidence].

Degos L.

Presse Med. 2010 Jul-Aug;39(7-8):743-4. doi: 10.1016/j.lpm.2010.05.003. Epub 2010 Jun 16. French. No abstract available.

PMID:
20558029
13.

Suitability of three indicators measuring the quality of coordination within hospitals.

Minvielle E, Leleu H, Capuano F, Grenier C, Loirat P, Degos L.

BMC Health Serv Res. 2010 Apr 8;10:93. doi: 10.1186/1472-6963-10-93.

14.

Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies.

Falissard B, Izard V, Xerri B, Bouvenot G, Meyer F, Degos L.

Int J Technol Assess Health Care. 2010 Jan;26(1):124-30. doi: 10.1017/S0266462309990821.

PMID:
20059790
15.

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, Gardin C, Fegeux N, Bordessoule D, Ferrant A, Meyer-Monard S, Vey N, Dombret H, Degos L, Chevret S, Fenaux P; European APL Group.

Blood. 2010 Mar 4;115(9):1690-6. doi: 10.1182/blood-2009-07-233387. Epub 2009 Dec 17.

PMID:
20018913
16.

Viewing the safety imperative from the French policy perspective.

Amalberti R, Bruneau C, Desplanques A, Degos L.

Qual Saf Health Care. 2009 Dec;18(6):420-1. doi: 10.1136/qshc.2009.037036. No abstract available.

PMID:
19955449
17.

[Jean Dausset. Pioneer, discoverer and responsible].

Degos L.

Rev Prat. 2009 Sep 20;59(7):1030-3. French. No abstract available.

PMID:
19839480
18.

Jean Dausset a scientific pioneer: intuition and creativity for the patients (1916-2009).

Degos L.

Haematologica. 2009 Sep;94(9):1331-2. doi: 10.3324/haematol.2009.014126. No abstract available.

19.

The "zero risk" concept for hospital-acquired infections: a risky business!

Carlet J, Fabry J, Amalberti R, Degos L.

Clin Infect Dis. 2009 Sep 1;49(5):747-9. doi: 10.1086/604720.

PMID:
19624275
20.

Adverse events in medicine: easy to count, complicated to understand, and complex to prevent.

Amalberti R, Benhamou D, Auroy Y, Degos L.

J Biomed Inform. 2011 Jun;44(3):390-4. doi: 10.1016/j.jbi.2009.06.004. Epub 2009 Jul 15.

21.

Breaking the mould in patient safety.

Degos L, Amalberti R, Bacou J, Carlet J, Bruneau C.

BMJ. 2009 Jun 29;338:b2585. doi: 10.1136/bmj.b2585. No abstract available.

PMID:
19564180
22.

[Self-medication, patients as actors in their own health].

Degos L.

Bull Acad Natl Med. 2007 Nov;191(8):1503-7; discussion 1507-8. French.

PMID:
18666451
23.

[Developing health services research in France, one of the HAS missions].

Michel P, Romaneix F, Degos L.

Rev Epidemiol Sante Publique. 2008 Jul;56 Suppl 3:S177-8. doi: 10.1016/j.respe.2008.04.002. Epub 2008 Jun 6. French. No abstract available.

PMID:
18538960
24.

Can France keep its patients happy?

Degos L, Romaneix F, Michel P, Bacou J.

BMJ. 2008 Feb 2;336(7638):254-7. doi: 10.1136/bmj.39451.406123.AD. No abstract available.

25.

Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology.

Delva L, Zelent A, Naoe T, Fenaux P, Waxman S, Degos L, Chomienne C.

Cancer Res. 2007 Nov 15;67(22):10635-7. Epub 2007 Nov 9. No abstract available.

26.

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, Pabst T, Thomas X, de Botton S, Parody R, Bergua J, Lamy T, Vekhoff A, Negri S, Ifrah N, Dombret H, Ferrant A, Bron D, Degos L, Fenaux P.

Blood. 2008 Feb 1;111(3):1078-84. Epub 2007 Nov 1.

PMID:
17975017
27.

[The French National Authority for Health].

Degos L.

Bull Acad Natl Med. 2006 Oct;190(7):1327-37; discussion 1337-8. French.

PMID:
17450670
28.

Treatment of acute promyelocytic leukemia by retinoids.

Fenaux P, Wang ZZ, Degos L.

Curr Top Microbiol Immunol. 2007;313:101-28. Review.

PMID:
17217041
29.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.

PMID:
17116939
30.

Jean Bernard. Medicine, science, humanity.

Degos L.

Haematologica. 2006 Sep;91(9):1163-4. No abstract available.

PMID:
16956813
31.

Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).

Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P.

Leukemia. 2006 May;20(5):905-7. No abstract available.

PMID:
16541143
32.

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L, Fenaux P; European APL Group; PETHEMA Group.

Leukemia. 2006 Jan;20(1):35-41.

PMID:
16307026
33.

Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.

Raffoux E, Chaibi P, Dombret H, Degos L.

Haematologica. 2005 Jul;90(7):986-8.

34.

Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy.

Zelent A, Petrie K, Chen Z, Lotan R, Lübbert M, Tallman MS, Ohno R, Degos L, Waxman S.

Cancer Res. 2005 Feb 15;65(4):1117-23.

35.

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.

Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, Dela Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P; European APL Group.

Leukemia. 2005 Feb;19(2):230-3.

PMID:
15565164
36.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P.

J Clin Oncol. 2005 Jan 1;23(1):120-6. Epub 2004 Nov 8.

PMID:
15534358
37.

[Future vision of haematology].

Degos L.

Presse Med. 2004 Jun 15;33 Spec No:Sp64-6. French. No abstract available.

PMID:
15360151
38.

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.

Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, Degos L, Dombret H, Toubert A, Rea D.

Leukemia. 2004 Oct;18(10):1656-61.

PMID:
15343347
39.

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.

Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de Revel T, Simon M, Dupriez B, Renoux M, Janvier M, Micléa JM, Thomas X, Bastard C, Preudhomme C, Bauters F, Degos L, Dombret H.

Blood. 2004 Oct 15;104(8):2467-74. Epub 2004 May 13.

PMID:
15142880
40.

Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.

de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P.

J Clin Oncol. 2004 Apr 15;22(8):1404-12.

PMID:
15084614
41.

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Hermine O, Dombret H, Poupon J, Arnulf B, Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de Thé H, Bazarbachi A.

Hematol J. 2004;5(2):130-4.

PMID:
15048063
42.

Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).

Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H.

J Invest Dermatol. 2003 Oct;121(4):881-93.

43.

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E, Bastie JN, Degos L, Berthaud P, Marolleau JP, Calvo F, Chomienne C, Mahon FX, Rousselot P.

Biochem Pharmacol. 2003 Nov 15;66(10):1907-13.

PMID:
14599548
44.

PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.

Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C.

Nat Med. 2003 Nov;9(11):1413-7. Epub 2003 Oct 19.

PMID:
14566333
45.

The history of acute promyelocytic leukaemia.

Degos L.

Br J Haematol. 2003 Aug;122(4):539-53. No abstract available.

PMID:
12899709
46.

Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.

Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, Ferrant A, Sanz M, Fey M, Chomienne C, Chevret S, Degos L, Fenaux P; European APL group experience.

Leukemia. 2003 Aug;17(8):1600-4.

PMID:
12886249
47.

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H.

J Clin Oncol. 2003 Jun 15;21(12):2326-34.

PMID:
12805334
48.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial.

de Botton S, Chevret S, Coiteux V, Dombret H, Sanz M, San Miguel J, Caillot D, Vekhoff A, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Fey M, Cony Makhoul D, Reman O, de la Serna J, Lefrere F, Chomienne C, Degos L, Fenaux P; European APL group.

Leukemia. 2003 Feb;17(2):339-42.

PMID:
12592333
49.

In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.

Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, Janin A, Daniel MT, Gourmel B, Degos L, Dombret H, Lanotte M, De Thé H.

J Exp Med. 2002 Nov 18;196(10):1373-80.

50.

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.

Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, Tigaud I, Raffoux E, Rousselot P, Sigaux F, Degos L, Castaigne S, Fenaux P, Dombret H.

Leukemia. 2002 Sep;16(9):1699-704.

Supplemental Content

Support Center